Ownership Capital B.V. Decreases Holdings in Veeva Systems Inc. (NYSE:VEEV)

Ownership Capital B.V. trimmed its stake in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,088,483 shares of the technology company's stock after selling 33,083 shares during the period. Veeva Systems comprises about 4.7% of Ownership Capital B.V.'s portfolio, making the stock its 11th largest position. Ownership Capital B.V. owned about 0.68% of Veeva Systems worth $209,555,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Sequoia Financial Advisors LLC increased its stake in Veeva Systems by 703.8% in the 4th quarter. Sequoia Financial Advisors LLC now owns 15,594 shares of the technology company's stock valued at $3,002,000 after buying an additional 13,654 shares during the last quarter. Nordea Investment Management AB increased its stake in Veeva Systems by 5.2% in the 4th quarter. Nordea Investment Management AB now owns 163,247 shares of the technology company's stock valued at $31,730,000 after buying an additional 8,007 shares during the last quarter. ICICI Prudential Asset Management Co Ltd increased its stake in Veeva Systems by 13.1% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 49,140 shares of the technology company's stock valued at $9,460,000 after buying an additional 5,674 shares during the last quarter. Lecap Asset Management Ltd. bought a new position in shares of Veeva Systems in the 4th quarter valued at about $2,668,000. Finally, DekaBank Deutsche Girozentrale grew its position in shares of Veeva Systems by 26.3% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 98,377 shares of the technology company's stock valued at $18,953,000 after acquiring an additional 20,488 shares during the period. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Jonathan Faddis sold 3,598 shares of the company's stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $207.42, for a total transaction of $746,297.16. Following the completion of the transaction, the senior vice president now directly owns 10,668 shares in the company, valued at approximately $2,212,756.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Veeva Systems news, EVP Alan Mateo sold 3,391 shares of the business's stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $200.86, for a total transaction of $681,116.26. Following the sale, the executive vice president now directly owns 21,983 shares of the company's stock, valued at approximately $4,415,505.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jonathan Faddis sold 3,598 shares of the business's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $207.42, for a total transaction of $746,297.16. Following the sale, the senior vice president now directly owns 10,668 shares in the company, valued at $2,212,756.56. The disclosure for this sale can be found here. Insiders sold a total of 21,989 shares of company stock worth $4,818,013 in the last three months. 10.98% of the stock is owned by corporate insiders.

Veeva Systems Stock Up 0.9 %

Shares of NYSE:VEEV traded up $1.82 during midday trading on Friday, hitting $200.91. The stock had a trading volume of 848,504 shares, compared to its average volume of 941,040. The company's 50-day moving average price is $219.27 and its 200-day moving average price is $202.55. The company has a market capitalization of $32.41 billion, a P/E ratio of 62.39, a price-to-earnings-growth ratio of 2.01 and a beta of 0.74. Veeva Systems Inc. has a fifty-two week low of $160.21 and a fifty-two week high of $236.90.

Veeva Systems (NYSE:VEEV - Get Free Report) last issued its earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. The company had revenue of $630.62 million during the quarter, compared to analysts' expectations of $620.75 million. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. Research analysts expect that Veeva Systems Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Oppenheimer reissued an "outperform" rating and issued a $225.00 price objective on shares of Veeva Systems in a research report on Thursday, February 22nd. Truist Financial lifted their price objective on shares of Veeva Systems from $187.00 to $203.00 and gave the company a "hold" rating in a research report on Friday, March 1st. Barclays lifted their target price on shares of Veeva Systems from $240.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, March 1st. StockNews.com raised shares of Veeva Systems from a "hold" rating to a "buy" rating in a report on Friday, April 12th. Finally, The Goldman Sachs Group lifted their target price on shares of Veeva Systems from $219.00 to $248.00 and gave the stock a "buy" rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $234.90.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.